Gene · 862
NIH grants2,053
NIH grants whose papers are about the gene, through NIH's grant-paper links.
221 to 240 of 2,053
Download this page as JSON| Grant | Title | RUNX1T1 papers | Newest fiscal year |
|---|---|---|---|
| R01CA208148 | Computational methods to decipher somatic alterations in cancer genomes | 1 | 2025 |
| R01CA214799 | Compensatory Mechanisms that Promote Homologous Recombination in BRCA1 Mutant Cancers | 1 | 2025 |
| R01CA218285 | Immuno and Epigenetics of Hematopoietic Cell Transplantation | 1 | 2025 |
| R01CA241752 | Targeting MUC5AC mucin in breast cancer brain metastasis | 1 | 2025 |
| R01CA247883 | Roles of Coactivator-Associated Arginine Methyltransferase 1 in B cell activation and lymphomagenesis | 1 | 2025 |
| R01CA247943 | Mechanisms of differentiation blockade in CSF3R-mutant AML | 1 | 2025 |
| R01CA248381 | Leveraging the TCR Repertoire to identify target neoantigens in FLT3-ITD positive Acute Myeloid Leukemia | 1 | 2025 |
| R01CA248984 | DISSECTING THE ROLE OF PRDM15 IN NORMAL HEMATOPOIESIS AND B-CELL MALIGNANCIES | 1 | 2025 |
| R01CA255331 | Therapeutic resistance and aggressive malignancy in glioblastomas: the contribution of GTP metabolism through regulation by IMPDH2 | 1 | 2025 |
| R01CA260711 | Impact of mutational order on molecular mechanisms of oncogenesis | 1 | 2025 |
| R01CA262012 | Backtracking Leukemia-Typical Somatic Alterations in Cord Blood at Single-cell Resolution | 1 | 2025 |
| R01CA262746 | Molecular Pathogenesis of AF10-Rearranged Leukemias | 1 | 2025 |
| R01CA262758 | Mechanisms of venetoclax combination activity in acute myeloid leukemia | 1 | 2025 |
| R01CA266253 | Genomics of childhood acute lymphoblastic leukemia in the Childhood Cancer and Leukemia International Consortium | 1 | 2025 |
| R01CA270120 | Integrated Systems Biology of Pediatric AML | 1 | 2025 |
| R01CA271331 | Mechanisms and therapeutic implications of human clonal hematopoiesis (CH) mutations | 1 | 2025 |
| R01CA271455 | Dissecting innate immune signaling in pre-leukemia evolution | 1 | 2025 |
| R01CA273326 | Tracking Therapy-Resistant Alterations in Childhood Acute Lymphoblastic Leukemia | 1 | 2025 |
| R01DK047420 | Nuclear Events in PTHR1 Action on Bone | 1 | 2025 |
| R01DK050107 | Transcriptional Control of Hemoglobin Synthesis and Erythrocyte Development | 1 | 2025 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/862/grants?page=12